Advances in the Microbiome: Applications to Clostridium difficile Infection
AbstractClostridium difficile is a major cause of morbidity and mortality worldwide, causing over 400,000 infections and approximately 29,000 deaths in the United States alone each year. C. difficile is the most common cause of nosocomial diarrhoea in the developed world, and, in recent years, the emergence of hyper-virulent (mainly ribotypes 027 and 078, sometimes characterised by increased toxin production), epidemic strains and an increase in the number of community-acquired infections has caused further concern. Antibiotic therapy with metronidazole, vancomycin or fidaxomicin is the primary treatment for C. difficile infection (CDI). However, CDI is unique, in that, antibiotic use is also a major risk factor for acquiring CDI or recurrent CDI due to disruption of the normal gut microbiota. Therefore, there is an urgent need for alternative, non-antibiotic therapeutics to treat or prevent CDI. Here, we review a number of such potential treatments which have emerged from advances in the field of microbiome research. View Full-Text
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Culligan, E.P.; Sleator, R.D. Advances in the Microbiome: Applications to Clostridium difficile Infection. J. Clin. Med. 2016, 5, 83.
Culligan EP, Sleator RD. Advances in the Microbiome: Applications to Clostridium difficile Infection. Journal of Clinical Medicine. 2016; 5(9):83.Chicago/Turabian Style
Culligan, Eamonn P.; Sleator, Roy D. 2016. "Advances in the Microbiome: Applications to Clostridium difficile Infection." J. Clin. Med. 5, no. 9: 83.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.